Drug Approval | July 15, 2022
U.S. FDA grants emergency use authorization for Novavax COVID-19 vaccine
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
MedTel aims to raise series A for rapid business expansion, product improvement & conducting relevant clinical validation studies.
Medicfibers in collaboration with AIIMS New Delhi, has developed an antimicrobial solution Viroclog that when applied as a coating on textiles, provides long-lasting protection against HAI by reducing virus, bacteria, fungi survival on fabric
Company is investing more than €100 million in the expansion of the Halle site
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
It is a two dose vaccine to be administered intramuscularly at 28 days apart
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Subscribe To Our Newsletter & Stay Updated
